Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Zealand cashes out rusfertide royalty for USD 100m ahead of FDA decision

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

Zealand Pharma has sold its 1% royalty interest in rusfertide to Royalty Pharma for USD 100 million, converting future royalty income into immediate capital ahead of an anticipated FDA decision on the drug in Q3 2026.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Drug developers with royalty streams can unlock significant cash by selling royalty rights ahead of regulatory decisions. You can fund growth without diluting equity by converting future payments into capital now.

◆ Coverage

1 source · 13 Aug 2026

◆ Related on Wire

◆ Topics

Biotechroyalty-saleFDA-approvalbiotech-financedrug-commercialisation